Apalutamide and Goserelin for Androgen Receptor-Positive Salivary Gland Carcinoma: A Phase II Nonrandomized Clinical Trial, YATAGARASU.

Yoshitaka Honma Nobuya Monden Keisuke Yamazaki Satoshi Kano Hironaga Satake Shigenori Kadowaki Yoshitaka Utsumi Tomohiko Nakatogawa Ryo Takano Koji Fujii Yosuke Koroki Junya Aoyama Shohei Ouchi Tetsuro Ogawa Sharon McCarthy Sabine D Brookman-May Suneel D Mundle Jinhui Li Daksh Thaper Toshitaka Nagao Yuichiro Tada

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

Although this study did not meet the predefined efficacy criteria, apalutamide plus goserelin showed clinically meaningful efficacy in a subset of patients with AR-positive salivary gland carcinoma and safety consistent with prior experience in prostate cancer.

Keyphrases

phase ii
clinical trial
prostate cancer
open label
phase iii
double blind
placebo controlled
study protocol
randomized controlled trial